Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06790706
Title	IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers (IMMUNORARE5)
Acronym	IMMUNORARE5
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Hospices Civils de Lyon
Indications	neuroendocrine tumor epithelioid trophoblastic tumor malignant epithelial mesothelioma sarcomatoid mesothelioma gestational trophoblastic neoplasm malignant biphasic mesothelioma placental site trophoblastic tumor thymoma anaplastic thyroid carcinoma thymic carcinoma pulmonary neuroendocrine tumor gastrointestinal neuroendocrine tumor peritoneal mesothelioma
Therapies	AB154 + Zimberelimab AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab
Age Groups:	adult \| senior
Covered Countries	FRA